# A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)

> **NCT01025713** · PHASE1 · WITHDRAWN · sponsor: **Gilead Sciences**

## Conditions studied

- Cystic Fibrosis
- Mucociliary Clearance

## Interventions

- **DRUG:** GS-9411
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01025713
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-12
- **Primary completion:** 2010-03
- **Final completion:** 2010-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Development program terminated.
- **Last updated:** 2015-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01025713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01025713, "A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01025713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*